| 摘要 |
PURPOSE: To prepare a pharmeceutical composition, comprising a human interferon-β(LFN-β) and effective in treating disorders characterized by the lack in maturation of progenitor blood cells to red blood cells. CONSTITUTION: This pharmaceutical composition comprises a natural IFN-βproduced by an induced fibroblast or a recombinant IFN-βproduced by a genetic engineering technique (preferably the one produced by a Chinese hamster ovarian cell) and is capable of promoting rapid maturation of progenitor blood cells to normal blast cells and anaphase reticulocytes. The composition is effective in treating osteomyelodysplasia syndrome, anemia, sideroblastic anemia, refractory anemia, myelofibrosis, chronic myelomonocytic leukemia, chronic myelocytic leukemia, anemia caused by chronic infectious disorders and anemia caused by rheumatic arthritis.
|
